Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantationopen access
- Authors
- Uhm, Jieun
- Issue Date
- Apr-2023
- Publisher
- Korean Society of Hematology
- Keywords
- Chronic myeloid leukemia; Tyrosine kinase inhibitors; Ponatinib; Asciminib; Allogeneic hematopoietic stem cell transplantation
- Citation
- Blood Research, v.58, pp.S109 - S113
- Indexed
- SCOPUS
KCI
- Journal Title
- Blood Research
- Volume
- 58
- Start Page
- S109
- End Page
- S113
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/191980
- DOI
- 10.5045/br.2023.2023054
- ISSN
- 2287-979X
- Abstract
- The treatment outcomes of chronic myeloid leukemia in chronic phase (CML-CP) have dramatically improved with comparable life-expectancy to average of general population in tyrosine kinase inhibitor (TKI) era. However, less than a half of patients who started with TKI can remain on frontline TKI. The reasons of switching TKI can be either intolerance or the lack of efficacy. Although a kinase domain (KD) mutation can guide to select salvage TKI from the point of view on the efficacy of TKIs, many factors need to be considered before choosing next-line TKI such as the high-risk features of CML, the adverse events with prior TKI, and the comorbidities of patients. The therapeutic options for CML-CP after failing frontline TKI due to treatment failure or suboptimal responses will be reviewed including allogeneic hematopoietic stem cell transplantation.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/191980)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.